SIAIS178 represents an innovative proteolysis-targeting chimeric (PROTAC) degrader—a unique hybrid molecule intertwining the BCR-ABL kinase inhibitor dasatinib with a ligand designed for the Von Hippel-Lindau (VHL) E3 ubiquitin ligase through an optimized linker. It effectively directs the BCR-ABL protein for degradation through VHL-mediated mechanisms.
Usually ships within 24 hours.